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Recent advances in molecular technology suggest the potential for
more efficient and effective molecular-based diagnoses and thera-
pies. Many studies, such as those concerning p53, RAS, RET, and
thyrotropin receptor, have improved our understanding of thyroid
carcinogenesis (Farid, 1996). However, more intensive studies 
to further clarify the molecular mechanism of carcinogenesis 
are necessary before we select the molecular targets for these
technologies. 
In the thyroid, as in other organs, genes that are found to 
be differentially expressed between normal thyroid tissue and 
thyroid carcinomas can be used as targets for molecular-based
diagnosis and therapy (Chiappetta et al, 1998; Takano et al, 
1998, 1999). Recent developments in technologies aimed at
identifying differentially expressed genes, such as differential
hybridization and differential display, have identified some genes
the expression of which is restricted to thyroid carcinomas
(Gonsky et al, 1997; Takano et al, 1997; de Nigris et al, 1998).
However, the data made available by these methods are still insuf-
ficient for a comprehensive evaluation of all genes involved in
carcinogenesis. 
By relying on 14–15 base cDNA sequences for gene identifica-
tion, serial analysis of gene expression (SAGE) can generate a
quantitative transcript profile easily, a task currently not possible
using alternative transcript imaging technologies (Velculescu et al,
1995), and is less laborious than the body mapping method which
can generate similar profiles (Matsubara and Okubo, 1993). Since
its introduction in 1995, SAGE has been used to analyse cDNA
libraries derived from several carcinomas and its reliability has
been established (Zhang et al, 1997; Hibi et al, 1998). We describe
here the use of SAGE to provide gene expression profiles in 
normal thyroid and thyroid tumours, a technique that may lead 
to an enhanced understanding of thyroid cell function and
carcinogenesis. 
MATERIALS AND METHODS 
Materials 
Tissue samples for SAGE were obtained surgically from a normal
thyroid tissue adjacent to a follicular adenoma in a 43-year-old
female, a follicular adenoma in a 43-year-old female, a papillary
carcinoma in a 32-year-old female, a widely invasive follicular
carcinoma in a 35-year-old female, and an anaplastic carcinoma in
a 77-year-old female. Tissue samples from three normal thyroids,
follicular adenomas, papillary carcinomas, follicular carcinomas
and anaplastic carcinomas were also collected for reverse
transcription-polymerase chain reaction (RT-PCR) analysis.
Thyroid tumours were classified histopathologically according to
the WHO histological classification of thyroid tumours (Hedinger
et al, 1989). Total cellular RNA was extracted according to the
method of Chomczynski and Sacchi (Chomczynski and Sacchi,
1987) and poly A RNA was purified with oligotex-dT30 (Takara,
Shiga, Japan) according to the manufacturer’s protocol. 
SAGE protocol 
The SAGE method was performed as described previously with
some modifications. 3 µ g of poly A RNA was converted to double-
stranded cDNA with a BRL synthesis kit (Gibco BRL, Tokyo,
Japan) according to the manufacturer’s protocol except for the
inclusion of primer biotin-5′ -T18-3′ . The cDNA was cleaved with
Nla III (anchoring enzyme) (Daiichi-Kagaku, Tokyo, Japan). After
capture of the 3′ cDNA fragments on streptavidin-coated magnetic
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two pools, and one of the following linkers containing a recognition
site for Bsm FI (Daiichi-Kagaku) was ligated to each pool: 
linker 1, 5′ -TTTGGATTTGCTGGTGCAGTACAACTAG-
GCTTAATAGGGACATG-3′ , 5′ -TCCCTATTAAGCC-
TAGTTGTAXTGCACCAGCAAATCC (amino modification
C7)-3′ ;
linker 2, 5′ -TTTCTGCTCGAATTCAAGCTTCTAACGATG-
TACGGGGACATG-3′ ,5 ′ -TCCCCGTACATCGTTA-
GAAGCTTGAATTCGAGCAG (amino modification C7)-3′ . 
Since Bsm FI (tagging enzyme) cleaves 14 bp away from its
recognition site, and the Nla III site overlaps the Bsm FI site by 
1 bp, a 15 bp SAGE tag was released with Bsm FI, SAGE tag
overhangs were filled in with Klenow (Takara), and tags from 
the two pools were combined and ligated to each other. The
ligation product was amplified by 15 cycles of PCR using 
5′ -GGATTTGCTGGTGCAGTACA-3′ and 5′ -CTGCTCGAAT-
TCAAGCTTCT-3′ as primers. All the linkers and primers were
obtained from Gibco BRL. The PCR products were analysed by
polyacrylamide gel electrophoresis (PAGE), and the PCR product
containing two tags ligated tail to tail (ditag) was excised. The
PCR product was re-amplified by 20 cycles of PCR using the same
primers, purified by PAGE, then cleaved with Nla III. The band
containing the ditags was excised and self-ligated, then cleaved
with Sph I (Takara). The concatenated products were separated by
gel filtration using a Sephadex 400R (Amersham Pharmacia,
Tokyo, Japan), then cloned into the Sph I site of pGEM-5Zf (+)
(Promega, Tokyo, Japan). These procedures produced about 500
white colonies per reaction. Colonies were screened for inserts by
PCR using primers which sequences located outside the cloning
site. Colonies containing inserts of about 400 bp in length were
selected for the further analysis. Plasmids from selected clones
were purified by an automatic plasmid isolation system 
PI-100  (Kurabo, Osaka, Japan) then sequenced with Taq FS Dye
Primer kits (PE Biosystems, Tokyo, Japan) and analysed using 
a 373 ABI automated sequencer (PE Biosystems), following 
the manufacturer’s protocol. Sequence files were analysed 
by the SAGE software and the tag sequences were analysed by the
BLAST program of the DNA Data Bank of Japan (Mishima,
Sizuoka, Japan). The occurrence rates of tag sequences were
calculated by dividing the number of occurrences of a particular
tag sequence by the total tag count. 
Semi-quantitative RT-PCR analysis 
Semi-quantitative RT-PCR analyses of 4 representative mRNA
sequences were performed as previously described (Takano et al,
1997). The sequence of the 5′ primers are 5′ -GGATTTGCTGGT-
GCAGTACA-3′ (base 1511–1530) (Swaroop et al, 1988) for
1496 T Takano et al 
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Table 1 SAGE analysis of a normal thyroid and a follicular adenoma 
Normal thyroid Follicular adenoma
Total no. of tags = 5411, no. of unique tags = 623 Total no. of tags = 5030, no. of unique tags = 569
Count Sequence Definition Count Sequence Definition
64 CCACTGCACT EST A1081056 144 CGGTGAAAAA thyroglobulin
63 CGGTGAAAAA thyroglobulin 56 CCTGTAATCC 5′ -nucleotidase
55 ACTTTTTCAA mitochondrial cytochrome oxidase subunit 1 54 ACTTTTTCAA mitochondrial cytochrome oxidase subunit 1
50 GTGAAACCCC(G) 1. Alu transcript 54 CCACTGCACT EST AI081056
2. obese protein 47 CGGTGAAGCA no match
3. platelet-activating factor acetylhydrolase 2 38 GTGAAACCCT putative serine-threonine protein kinase
49 CCTGTAATCCC 5’-nucleotidase 34 TGTGTTGAGA elongation factor 1-alpha
48 GTGAAACCCC(A) 1. granulocyte-macrophage 33 GTGAAACCCC(G) 1. Alu transcript
colony-stimulating factor receptor  2. obese protein
alpha-subunit soluble isoform 2 3. platelet-activating factor acetylhydrolase 2
2. myelin/oligodendrocyte glycoprotein-25.1kD 29 GTGAAACCCC(A) 1. granulocyte-macrophage colony-stimulating
3. fibroblast growth factor receptor factor receptor alpha-subunit soluble isoform 2
33 GTGAAACCCT putative serine-thereonine protein kinase 2. myelin/oligodendrocyte glycoprotein-25.1kD
30 TGTGTTGAGA elongation factor 1-alpha 3. fibroblast growth factor receptor
29 CACCTAATTG mitochondrial ATP synthase 6 23 TAGGTTGTCT translationally controlled tumor protein
28 AACCCGGGAG 1. transmembrane receptor protein 20 CACCTAATTG mitochondrial ATP synthase 6
2. primary Alu transcript 19 AGCTCTCCCT putative ribosomal protein L23
28 CCCATCGTCC mitochondrial cytochrome oxidase subunit 2 19 GGCAAGCCCC Csa-19
26 AGGGAGGGGC glutathione peroxidase 19 TTCATACACC mitochondrial NADH dehydrogenase 4
25 TCAAGCCATC EST AI563994 19 TTGGTCCTCT ribosomal protein L41
25 TTCATACACC mitochondrial NADH dehydrogenase 4 18 CCCATCGTCC mitochondrial cytochrome oxidase subunit 2
23 CTCCACCCGA secretory protein 17 AACCCGGGAG 1. transmebrane receptor protein
23 TACATAATTA trophoblast STAT 2. primary Alu transcript
20 AGCCCTACAA mitochondrial NADH dehydrogenase 3 17 AGCCCTACAA mitochondrial NADH dehydrogenase 3
20 GCGAAACCCC EST N71314 16 CCTCAGGATA mitochondrial NADH dehydrogenase 6
19 AACCTGGGAG DNA fragmentation factor-45 16 GCCGAGGAAG ribosomal protein S12
19 AGCTCTCCCT putative ribosomal protein L23 15 CACAAACGGT 1. metallopanstimulin
18 CTAAGACTTC EST C04521 2. ribosomal protein S27
18 TTGGCTTGCT EST AA515148 14 CCTGTAGTCC EST R10346
15 ACCCTTGGCC mitochondrial NADH dehydrogenase 1 14 TTGGCCAGGC 1. aggrecanase-1
15 AGGTCAGGAG human carcinoma cell-derived Alu RNA  2. interferon-inducible RNA-dependent 
transcript, clone CD139 protein kinase
15 CAAGCATCCC EST A1557493 3. glucose-6-phosphatase
15 CGCCGCCGGC ribosomal protein L35 13 CCAGAACAGA 1. ribosomal protein L30
2. thymidylate kinase 
14 GACGACACGA ribosomal protein S28 Gene expression in thyroid carcinomas 1497
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8osteonectin, 5′ -GGATTTGCTGGTGCAGTACA-3′ (base 1021–1040)
for  α -tubulin (Cowan et al, 1983), 5′ -CCAAGGTCATCCAT-
GACAAC (base 557–576) for glyceraldehydes-3-phosphate
dehydrogenase (GAPDH) (Arcari et al, 1984), and 5′ -ACGTGTC-
CTACCTATGTGTC-3′ (base 981–1000) for glutathione peroxi-
dase (Takahashi et al, 1990). A poly A-anchor primer DDR
(5′ -ATGCGAATTCGTTTTTTTTTTTTTTTTTTT-3′ ) was used
for the 3′ primer. RT was performed using 1 µ g of total RNA in an
RT mixture containing 40 mM Tris-HCl (pH 8.3), 75 mM KCl, 
10 mM DTT, 3 mM MgCl2, 0.5 mM dNTPs, 200 U Moloney
murine leukaemia virus reverse transcriptase (Gibco BRL), 2 U/µ l
RNase inhibitor (Takara), and 2.5 µ M oligodeoxythymidylic acid
(Gibco BRL) in a total volume of 20 µ l at 37˚C for 60 min. For
PCR, each reaction mixture consist of 1 µ l of cDNA, 0.5 µ M each
primer, 2 µ l of 10 × Ex Taq buffer (Takara), 1.6 µ l of 2 mM dNTP
mix (PE Biosystems) 0.5 U of Ex Taq polymerase (Takara), and
nuclease-free water to a final volume of 20 µ l. The reaction
mixture was subjected to 25 cycles of denaturation (94˚C; 1 min),
annealing (55˚C; 1 min), andextension (72˚C; 1 min). After 
PCR amplification, 5 µ l of reaction mixture was run on 1.5%
agarose gel. The gel was stained with SYBR Green I (Takara),
then analysed with a Fluor Imager (Molecular Dynamics,
Sunnyvale, CA). 
RESULTS 
SAGE libraries were constructed from mRNAs isolated from 
a normal thyroid tissue sample and four thyroid tumours. In total,
29 275 tags were sequenced, representing about 600 unique tags in
each tissue (Tables 1 and 2). The majority of the highly expressed
sequences in each tissue code mitochondorial and ribosomal
proteins. The tag sequence of thyroglobulin mRNA was highly
expressed in the normal thyroid and the 3 differentiated thyroid
tumours but not in the anaplastic carcinoma. In the 2 differentiated
carcinomas, high expression levels of the tag sequence of
cathepsin B were observed. In the anaplastic carcinoma, most of
the highly occurring tag sequences were derived from house-
keeping genes in addition to mitochondorial and ribosomal
sequences. Some sequences that were only seldom observed in the
differentiated carcinomas, such as those of osteonectin and col-
lagen genes, were also highly expressed.
To generate a profile of the relative gene expression patterns in
each tumour, the occurrences of each tag identified in the tumour
library were compared with those observed in the libraries of the
other tumours or of the normal thyroid. Representative sequences
are listed in Tables 3 and 4. The tag sequences that code mitochon-
dorial and ribosomal proteins were excluded from the lists. A
small number of tag sequences showed extreme differences in the
expression levels among the normal thyroid and differentiated
tumours. In contrast, among the 97 tag sequences which occurred
10 times or more, 29 (29.8%) and 27 (27.8%) sequences occurred
at rates 10-fold or more than those in papillary and follicular carcin-
omas, respectively, which indicates that the expression profile of
the anaplastic carcinoma is much different from those of the differ-
entiated carcinomas. 
Expression levels of some genes whose tag sequences were
differentially expressed in the anaplastic carcinoma were exam-
ined by semi-quantitative RT-PCR. Semi-quantitative RT-PCR
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osteonectin
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glutathione
peroxidase
M
N
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Figure 1 Semi-quantitative RT-PCR analysis of osteonectin, α -tubulin, GAPDH, and glutathione peroxidase mRNAs. Tissue samples from three normal
thyroids (N), follicular adenomas (FA), papillary carcinomas (PC), follicular carcinomas (FC) and anaplastic carcinomas (AC) were subjected to RT-PCR
analysis. PCR products were run on a 1.5% agarose gel, then the gel was stained with SYBR Green 1 (Takara). Arrows indicate the expected positions of the
PCR products. M: PHY maker (Takara) Gene expression in thyroid carcinomas 1499
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confirmed increased expression of osteonectin, α -tubulin, and
GAPDH, and decreased expression of glutathione peroxidase
mRNA in 3 anaplastic carcinomas (Figure 1). 
DISCUSSION 
In this study, we used SAGE to analyse cDNAs from tissues of a
normal thyroid and 4 thyroid tumours and created expression
profiles for each tissue. In our results, some tag sequences corres-
ponded to more than one gene. It was not possible, by means of
only SAGE-data analysis, to determine whether all of the corres-
ponding genes were expressed in the tissue. In the case of these
sequences, further analyses, such as Northern blot or quantitative
RT-PCR analyses, may be needed. Some tag sequences with no
homology to known genes appear on the list. These sequences
might be derived from some unknown genes, although the possi-
bility of interference by the individual variations in the 3′ untrans-
lated region of mRNAs should be also considered. 
Pauws et al recently described the application of SAGE to create
an expression profile of the normal thyroid (Pauws et al, 2000).
Their data are quite similar to ours in that the majority of the
highly expressed sequences coded mitochondorial or ribosomal
proteins and the thyroglobulin gene was highly expressed.
However, while they detected 24 tags of thyroid peroxidase, we
detected none in the normal thyroid tissue and only 2 in the follic-
ular adenoma. The effects of some endemic factors, such as iodine
uptake, may explain this discrepancy. Further, because we
performed SAGE analysis on a smaller scale than they did, only
about 600 unique genes were identified. Thus, the analyses were
limited to abundantly expressed sequences, and this is another
reason why most of the thyroid-specific genes with moderate or
low expression levels could not be detected. 
In our study, the tag sequences of some genes, such as thyro-
globulin, cathepsin B, and thymosin beta 10, were expressed in the
benign and malignant tumours in a manner similar to that in pre-
vious reports (Brabant et al, 1991; Shuja and Murnane, 1996;
Califano et al, 1998), suggesting the reliability of these SAGE
data. For example, the tag sequence of cathepsin B occurred at a
much higher rate in the papillary and follicular carcinomas than in
the normal thyroid or the follicular adenoma. 
In the anaplastic carcinomas, most of the highly occurring tag
sequences code mitochondorial proteins, ribosomal proteins, or
housekeeping genes, such as GAPDH. Interestingly, the products
of some of these genes are already being used as serum tumour
markers such as beta 2-microglobulin and ferritin. Thus, some of
the genes identified here and shown to have high occurrence rates
in thyroid carcinomas might be used as serum tumour markers of
thyroid malignancies. 
Osteonectin is a bone matrix protein synthesized by cells of 
the osteoblastic lineage, with a possible association having been
suggested between this protein and microcalcifications in some
malignant tissues (Bellahcene and Castronovo, 1995). The corres-
ponding tag sequence of osteonectin mRNA showed a high occur-
rence rate in anaplastic carcinoma, and over-expression of this
gene was confirmed by semi-quantitative RT-PCR. Osteonectin
expression may become a new marker of anaplastic carcinomas,
and the relationship between the expression of osteonectin and
these cancers’ aggressive biological characteristics may provide an
interesting focus of study. 
One of the most difficult distinctions in thyroid pathology is the
differentiation between benign follicular adenomas and follicular
carcinomas (Rosai and Carcangiu, 1987). Preoperative differentia-
tion of follicular adenomas and carcinomas by cytopathological
examination is quite difficult; accordingly, there has been a
concentrated effort to establish a definite molecular marker of
follicular carcinoma. Although only several differentially ex-
pressed genes were identified in the present study, some of the
genes with known and unknown properties as listed in Table 3 may
be candidate markers of follicular carcinomas. 
In conclusion, in the present report, we analysed the gene
expression profiles in the normal thyroid and 4 representative
thyroid neoplasms. The results of this study may provide clues
toward not only the establishment of a molecular-based diagnosis
and therapy, but also an improved understanding of thyroid
function and tumorigenesis. 
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